ArticleInternational journal of molecular sciences2020
BMP-2/β-TCP Local Delivery for Bone Regeneration in MRONJ-Like Mouse Model.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Use of bmps as a treatment for medication-related maxillary osteonecrosis (mronj): a systematic review.Acta odontologica Scandinavica · 2026Pooled it
- 3D printed scaffolds loaded with BMP-2 for bone defect regeneration: a systematic review and meta-analysis.Frontiers in physiology · 2025Pooled it
- Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Calcium Phosphate Bone Substitutes in the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Review.Journal of functional biomaterials · 2026Review
- Adipose-Derived Mesenchymal Stem Cell Osteodifferentiation after Exposure to Beta-Tricalcium Phosphate Bioceramic Granules with 300 to 600 and 600 to 1,000 µm Sizes.European journal of dentistry · 2026Article
- Advanced biomaterial-based approaches for medication-related osteonecrosis of the jaw.Open life sciences · 2026Article
- Review
- Optimizing β-TCP with E-rhBMP-2-infused fibrin for vertical bone regeneration in a mouse calvarium model.Regenerative biomaterials · 2025Article
- Local E-rhBMP-2/β-TCP Application Rescues Osteocyte Dendritic Integrity and Reduces Microstructural Damage in Alveolar Bone Post-Extraction in MRONJ-like Mouse Model.International journal of molecular sciences · 2024Article
- Rat Calvaria Model Mimicking the Intraoral Lesion of Medication-Related Osteonecrosis in the Jaw: A Preliminary Test.Journal of clinical medicine · 2023Article
- Biocompatibility and osteointegration capability of β-TCP manufactured by stereolithography 3D printing:Open life sciences · 2023Article
- Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).International journal of oral science · 2022Review
- Biodegradable and Biocompatible Adhesives for the Effective Stabilisation, Repair and Regeneration of Bone.Bioengineering (Basel, Switzerland) · 2022Review
- Periodontal Tissue as a Biomaterial for Hard-Tissue Regeneration followingMaterials (Basel, Switzerland) · 2022Article
- Review
- Suppression of Bone Necrosis around Tooth Extraction Socket in a MRONJ-like Mouse Model by E-rhBMP-2 Containing Artificial Bone Graft Administration.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a severe pathological condition associated mainly with the long-term administration of bone resorption inhibitors, which are known to induce suppression of osteoclast activity and bone remodeling. Bone Morphogenetic Protein (BMP)-2 is known to be a strong inducer of bone remodeling, by directly regulating osteoblast differentiation and osteoclast activity. This study aimed to evaluate the effects of BMP-2 adsorbed onto beta-tricalcium phosphate (β-TCP), which is an osteoinductive bioceramic material and allows space retention, on the prevention and treatment of MRONJ in mice. Tooth extraction was performed after 3 weeks of zoledronate (ZA) and cyclophosphamide (CY) administration. For prevention studies, BMP-2/β-TCP was transplanted immediately after tooth extraction, and the mice were administered ZA and CY for an additional 4 weeks. The results showed that while the tooth extraction socket was mainly filled with a sparse tissue in the control group, bone formation was observed at the apex of the tooth extraction socket and was filled with a dense connective tissue rich in cellular components in the BMP-2/β-TCP transplanted group. For treatment studies, BMP-2/β-TCP was transplanted 2 weeks after tooth extraction, and bone formation was followed up for the subsequent 4 weeks under ZA and CY suspension. The results showed that although the tooth extraction socket was mainly filled with soft tissue in the control group, transplantation of BMP-2/β-TCP could significantly accelerate bone formation, as shown by immunohistochemical analysis for osteopontin, and reduce the bone necrosis in tooth extraction sockets. These data suggest that the combination of BMP-2/β-TCP could become a suitable therapy for the management of MRONJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.